307 related articles for article (PubMed ID: 27059714)
1. Effect of Potentially Inappropriate Use of Antimuscarinic Medications on Healthcare Use and Cost in Individuals with Overactive Bladder.
Suehs BT; Davis C; Franks B; Yuran TE; Ng D; Bradt J; Knispel J; Vassilakis M; Berner T
J Am Geriatr Soc; 2016 Apr; 64(4):779-87. PubMed ID: 27059714
[TBL] [Abstract][Full Text] [Related]
2. Impact of 2015 Update to the Beers Criteria on Estimates of Prevalence and Costs Associated with Potentially Inappropriate Use of Antimuscarinics for Overactive Bladder.
Suehs BT; Davis C; Ng DB; Gooch K
Drugs Aging; 2017 Jul; 34(7):535-543. PubMed ID: 28540648
[TBL] [Abstract][Full Text] [Related]
3. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder.
Ivanova JI; Hayes-Larson E; Sorg RA; Birnbaum HG; Berner T
J Med Econ; 2014 Oct; 17(10):741-50. PubMed ID: 25051328
[TBL] [Abstract][Full Text] [Related]
5. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.
Andersson KE; Sarawate C; Kahler KH; Stanley EL; Kulkarni AS
BJU Int; 2010 Jul; 106(2):268-74. PubMed ID: 19922546
[TBL] [Abstract][Full Text] [Related]
7. Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder.
Kachru N; Sura S; Chatterjee S; Aparasu RR
Drugs Aging; 2016 Oct; 33(10):755-763. PubMed ID: 27681701
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported reasons for discontinuing overactive bladder medication.
Benner JS; Nichol MB; Rovner ES; Jumadilova Z; Alvir J; Hussein M; Fanning K; Trocio JN; Brubaker L
BJU Int; 2010 May; 105(9):1276-82. PubMed ID: 19912188
[TBL] [Abstract][Full Text] [Related]
9. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR
Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205
[TBL] [Abstract][Full Text] [Related]
10. A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.
Bunniran S; Davis C; Kristy R; Ng D; Schermer CR; Uribe C; Suehs BT
Neurourol Urodyn; 2018 Jan; 37(1):177-185. PubMed ID: 28370541
[TBL] [Abstract][Full Text] [Related]
11. Predictors of discontinuing overactive bladder medications.
Brubaker L; Fanning K; Goldberg EL; Benner JS; Trocio JN; Bavendam T; Jumadilova Z
BJU Int; 2010 May; 105(9):1283-90. PubMed ID: 19912189
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
Nazir J; Hakimi Z; Guelfucci F; Khemiri A; Fatoye F; Blázquez AMM; González MH
BMC Urol; 2018 Sep; 18(1):76. PubMed ID: 30180826
[TBL] [Abstract][Full Text] [Related]
13. Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.
Kachru N; Holmes HM; Johnson ML; Chen H; Aparasu RR
Curr Med Res Opin; 2021 Aug; 37(8):1303-1313. PubMed ID: 33890538
[TBL] [Abstract][Full Text] [Related]
14. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.
Wielage RC; Perk S; Campbell NL; Klein TM; Posta LM; Yuran T; Klein RW; Ng DB
J Med Econ; 2016 Dec; 19(12):1135-1143. PubMed ID: 27326725
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder.
Pelletier EM; Vats V; Clemens JQ
Am J Manag Care; 2009 Mar; 15(4 Suppl):S108-14. PubMed ID: 19355799
[TBL] [Abstract][Full Text] [Related]
16. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
17. Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice.
Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Aguado-Jodar A; Ruíz-Torrejón A
Actas Urol Esp; 2014 Oct; 38(8):530-7. PubMed ID: 24630426
[TBL] [Abstract][Full Text] [Related]
18. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
19. Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population.
Johnson TM; Walker D; Lockefeer A; Jiang B; Nimke D; Lozano-Ortega G; Kimura T
Neurourol Urodyn; 2022 Nov; 41(8):1872-1889. PubMed ID: 36098417
[TBL] [Abstract][Full Text] [Related]
20. Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis.
Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
Adv Ther; 2024 May; 41(5):2086-2097. PubMed ID: 38520502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
